Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026

Tipranks - Tipranks - Thu Mar 19, 7:02AM CDT

Jazz Pharmaceuticals (JAZZ) announced that the company and its partners will present one oral and six poster presentations at the 2026 American Association for Cancer Research, AACR, Annual Meeting, taking place April 17-22, 2026, in San Diego. The research highlights meaningful progress across Jazz’s oncology portfolio, including new findings from company-sponsored research evaluating Ziihera, a HER2-targeted bispecific antibody; JZP898, an investigational, differentiated, conditionally activated interferon alpha-2b cytokine pro-drug designed for activation within the tumor microenvironment; and imipridone compounds including Modeyso, a protease activator of the mitochondrial caseinolytic protease P and a dopamine D2 receptor inhibitor.

Claim 70% Off TipRanks Premium

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on JAZZ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).